A Phase 3 interventional study of Naproxen Sodium ER (BAYH6689) and Placebo in Toothache, sponsored by Bayer. Completed at 3 sites in United States. Open to participants aged 16 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-08-25.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Toothache with a site in United States — 7 open to participants now, 7 under way, none of them phase 3. Toothache · United States.
Among the 55 studies in Toothache with a site in United States, this one is the 9th largest by enrollment of the 51 interventional ones that give a count, is one of 3 that started in 2008, is one of 11 in phase 3, and was the 7th registered.
143 studies on the registry are indexed under Toothache; 29 are open to participants now.
Browse Toothache studies →7 of the 55 studies in Toothache with a site in United States are open now. Recruiting first, the newest first:
Cytogel Pharma, LLC · Sites in United States
Ages 18–45 · Healthy volunteers
University of Florida · Sites in United States
Ages 18+ · Healthy volunteers
University of Maryland, Baltimore · Sites in United States
Ages 6–12 · Healthy volunteers
Cleveland Dental Institute · Sites in United States
Ages 20–60
University of California, San Francisco · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 15 Toothache studies recruiting now, 4 (27%) set no upper age limit and 11 (73%) stop at 75 or younger; 7 take children under 18; 10 take healthy volunteers.
This study: 16 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 23 · Phase 3 11 · Phase 4 10
First in 2004; this study’s year is marked. 3 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 312 is above the median of 86 across 124 interventional studies indexed under Toothache.
Median enrollment 193 across the 51 interventional studies, 82 across the 4 observational. Of the 45 that completed or were terminated, 30 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 55 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 133 (62%) have results posted.
Bayer has 5 studies filed under Toothache — fewer than ten, so there is no comparison to draw.
5 of the studies in Toothache with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04860141Loma Linda UniversityEfficacy of Preoperative Administration of Gabapentin in 3rd Molar Dental Extraction. | 2026-12 |
| NCT06330207University of FloridaAn Emergency Department (ED) Provider Centered Intervention for Non-Traumatic Dental Condition Management (NTDC) | 2027-02-01 |
| NCT07945431South Rampart Pharma, Inc.A Study Evaluating the Efficacy and Safety of Novel Non-Opioid SRP-001 in Acute Pain After Molar Extraction | 2027-02-28 |
| NCT06691269University of Maryland, BaltimorePhotobiomodulation and Tooth Analgesia | 2027-06 |
| NCT07905105Cytogel Pharma, LLCA Study of CYT-1010 in Healthy Volunteers and Participants With Acute Pain After Third Molar Extraction | 2027-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 55 studies in Toothache with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the analgesic efficacy of a single, oral dose of a naproxen sodium extended-release tablet, compared to placebo in postsurgical dental pain.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
single dose (1 tablet) ER Naproxen sodium 660 mg with a full glass of water (240ml) within 1 - 4 hours post dental surgery.
Drug: Naproxen Sodium ER (BAYH6689)
Single dose (1 tablet) of placebo with a full glass of water (240ml) within 1 - 4 hours post dental surgery.
Drug: Placebo
Analgesic efficacy in dental pain; per oral; 1 tablet extended release Naproxen Sodium; with a full glass of water within 4 hours post surgery
Inactive ingredient; per oral; 1 lactose based tablet; with a full glass of water within 4 hours post surgery
Summed Pain Intensity Difference (SPID)
Categorical pain intensity scale - no pain (0), mild pain (1), moderate pain (2), or severe pain (3) was used for all pain intensity assessments postdose. Time-weighted Sum Pain Intensity Difference (SPID) was calculated by multiplying the Pain Intensity Difference (PID) score at each postdose time point by the duration (in hours) since the preceding time point and then summing these values over 0-24 and 16-24 hours, respectively.
Time frame: 0 to 24 hours post dose
Total Pain Relief (TOTPAR)
Pain relief categorical rating scale - no relief (0), a little relief (1), some relief (2), a lot of relief (3), or complete relief (4) was used for all pain relief assessments postdose. Time weighted total pain relief (TOTPAR) was calculated by multiplying the pain relief score at each postdose time point by the duration (in hours) since the preceding time point and then summing these values.
Time frame: 0-24 hours post dose
Summed Pain Intensity Difference at Specific Time Intervals
Categorical pain intensity scale - no pain (0), mild pain (1), moderate pain (2), or severe pain (3) was used for all pain intensity assessments postdose. Time-weighted Sum Pain Intensity Difference (SPID) was calculated by multiplying the Pain Intensity Difference (PID) score at each postdose time point by the duration (in hours) since the preceding time point and then summing these values for 0-6, 0-12, 0-16 hour intervals, respectively.
Time frame: 0-16 hours post dose
Time to First Use of Rescue Medication
Time to first use of rescue medication was estimated using the Kaplan-Meier method and analyzed by a Log rank test stratified by trial site and baseline pain intensity (PI). The outcome measure is time to first use of rescue medication. The criteria are if adequate pain relief is not achieved, then subjects are permitted to take rescue medication.
Time frame: postdose to first use of rescue medication
Global Assessment of the Investigational Product as a Pain Reliever
Categorical Scale: Poor (0), Fair (1), Good (2), Very Good (3), Excellent (4).
Time frame: at 24 hours postdose or immediately before first use of rescue medication
Time to Onset of Effect
Time to onset of effect is defined as the time to meaningful pain relief, provided that the subjects experienced both "perceptible" and "meaningful" pain relief. Perceptible pain relief was defined as when the subject first began to feel any pain-relieving effect from the investigational product. Meaningful pain relief was defined as when the subject felt the degree of pain relief was meaningful to them.
Time frame: from postdose to onset of first perceptible and meaningful pain relief for up to 6 hours
| Milestone | Naproxen Sodium ER (BAYH6689) | Placebo |
|---|---|---|
| Started | 153 | 159 |
| Completed | 152 | 156 |
| Not completed | 1 | 3 |
| Withdrew: Lost to follow-up | 0 | 2 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 |
Categorical pain intensity scale - no pain (0), mild pain (1), moderate pain (2), or severe pain (3) was used for all pain intensity assessments postdose. Time-weighted Sum Pain Intensity Difference (SPID) was calculated by multiplying the Pain Intensity Difference (PID) score at each postdose time point by the duration (in hours) since the preceding time point and then summing these values over 0-24 and 16-24 hours, respectively.
| units on a scale | Naproxen Sodium ER (BAYH6689) | Placebo |
|---|---|---|
| SPID 0-24 | 25.9 ± 25.87 | -3.1 ± 18.40 |
| SPID16-24 | 8.8 ± 9.30 | -1.0 ± 6.89 |
Pain relief categorical rating scale - no relief (0), a little relief (1), some relief (2), a lot of relief (3), or complete relief (4) was used for all pain relief assessments postdose. Time weighted total pain relief (TOTPAR) was calculated by multiplying the pain relief score at each postdose time point by the duration (in hours) since the preceding time point and then summing these values.
| units on a scale | Naproxen Sodium ER (BAYH6689) | Placebo |
|---|---|---|
| TOTPAR 0 - 6 hours | 12.7 ± 7.81 | 3.1 ± 5.07 |
| TOTPAR 0 - 12 hours | 25.5 ± 17.06 | 5.5 ± 10.70 |
| TOTPAR 0 - 16 hours | 34.1 ± 23.49 | 7.2 ± 14.83 |
| TOTPAR 0 - 24 hours | 51.3 ± 36.41 | 10.9 ± 23.95 |
| TOTPAR 16 - 24 hours | 17.2 ± 13.37 | 3.7 ± 9.40 |
Categorical pain intensity scale - no pain (0), mild pain (1), moderate pain (2), or severe pain (3) was used for all pain intensity assessments postdose. Time-weighted Sum Pain Intensity Difference (SPID) was calculated by multiplying the Pain Intensity Difference (PID) score at each postdose time point by the duration (in hours) since the preceding time point and then summing these values for 0-6, 0-12, 0-16 hour intervals, respectively.
| units on a scale | Naproxen Sodium ER (BAYH6689) | Placebo |
|---|---|---|
| SPID 0 - 6 | 6.2 ± 5.7 | -0.4 ± 4.2 |
| SIPD 0 - 12 | 12.7 ± 12.3 | -1.4 ± 8.54 |
| SIPD 0 - 16 | 17.1 ± 16.85 | -2.0 ± 11.68 |
Time to first use of rescue medication was estimated using the Kaplan-Meier method and analyzed by a Log rank test stratified by trial site and baseline pain intensity (PI). The outcome measure is time to first use of rescue medication. The criteria are if adequate pain relief is not achieved, then subjects are permitted to take rescue medication.
| hours | Naproxen Sodium ER (BAYH6689) | Placebo |
|---|---|---|
| Time to First Use of Rescue Medication | 22.27 (1.07 to 22.27) | 1.90 (1.03 to 10.12) |
Categorical Scale: Poor (0), Fair (1), Good (2), Very Good (3), Excellent (4).
| units on a scale | Naproxen Sodium ER (BAYH6689) | Placebo |
|---|---|---|
| Global Assessment of the Investigational Product as a Pain Reliever | 2.3 ± 1.43 | 0.6 ± 1.04 |
Time to onset of effect is defined as the time to meaningful pain relief, provided that the subjects experienced both "perceptible" and "meaningful" pain relief. Perceptible pain relief was defined as when the subject first began to feel any pain-relieving effect from the investigational product. Meaningful pain relief was defined as when the subject felt the degree of pain relief was meaningful to them.
| hours | Naproxen Sodium ER (BAYH6689) | Placebo |
|---|---|---|
| Time to Onset of Effect | 1.37 (0.07 to 4.98) | 4.13 (0.07 to 4.75) |
Collected over Adverse events were recorded throughout the treatment period through 5 days after investigational product or placebo administration. All Serious Adverse Events were collected through about 30 days after the last dose of investigational product or placebo.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Naproxen Sodium ER (BAYH6689) | — | 0/153 (0%) | 10/153 (6.5%) |
| Placebo | — | 0/159 (0%) | 36/159 (22.6%) |
| Event | Naproxen Sodium ER (BAYH6689) | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 3/153 | 24/159 |
| VomitingGastrointestinal disorders | 2/153 | 14/159 |
| DizzinessNervous system disorders | 1/153 | 8/159 |
| HeadacheNervous system disorders | 5/153 | 6/159 |
| Tooth Socket HaemorrhageGastrointestinal disorders | 1/153 | 2/159 |
| Eye SwellingEye disorders | 1/153 | 0/159 |
| PyrexiaGeneral disorders | 1/153 | 0/159 |
| Abscess OralInfections and infestations | 1/153 | 0/159 |
| SyncopeNervous system disorders | 1/153 | 1/159 |
| Pharyngolaryngeal PainRespiratory, thoracic and mediastinal disorders | 1/153 | 0/159 |
| Age, Continuous(years) | Naproxen Sodium ER (BAYH6689) | Placebo | Total |
|---|---|---|---|
| Mean | 20.8 ± 4.03 | 20.4 ± 4.31 | 20.6 ± 4.17 |
| Sex: Female, Male(Participants) | Naproxen Sodium ER (BAYH6689) | Placebo | Total |
|---|---|---|---|
| Female | 89 | 106 | 195 |
| Male | 64 | 53 | 117 |
| Baseline Pain Intensity by Categorical Scale(participants) | Naproxen Sodium ER (BAYH6689) | Placebo | Total |
|---|---|---|---|
| Moderate | 99 | 103 | 202 |
| Severe | 54 | 56 | 110 |
| Baseline Pain Intensity by Visual Analog Scale(scores on a scale) | Naproxen Sodium ER (BAYH6689) | Placebo | Total |
|---|---|---|---|
| Mean | 72.3 ± 13.13 | 72.6 ± 11.91 | 72.4 ± 12.51 |
The record gives a start of Jun 2008, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2011, 2 years 5 months after primary completion. A results delay was requested in Dec 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Naproxen